Stifel Financial’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-19,247
| Closed | -$368K | – | 3395 |
|
|
2023
Q4 | $368K | Buy |
19,247
+3,551
| +23% | +$61.4K | ﹤0.01% | 2728 |
|
|
2023
Q3 | $252K | Buy |
15,696
+1,592
| +11% | +$30.3K | ﹤0.01% | 2878 |
|
|
2023
Q2 | $327K | Sell |
14,104
-444
| -3% | -$9.69K | ﹤0.01% | 2771 |
|
|
2023
Q1 | $338K | Buy |
14,548
+1,992
| +16% | +$40.5K | ﹤0.01% | 2732 |
|
|
2022
Q4 | $182K | Sell |
12,556
-4,998
| -28% | -$93.1K | ﹤0.01% | 2999 |
|
|
2022
Q3 | $335K | Buy |
17,554
+897
| +5% | +$20.6K | ﹤0.01% | 2659 |
|
|
2022
Q2 | $303K | Sell |
16,657
-1,188
| -7% | -$24.7K | ﹤0.01% | 2744 |
|
|
2022
Q1 | $450K | Sell |
17,845
-976
| -5% | -$25K | ﹤0.01% | 2632 |
|
|
2021
Q4 | $519K | Sell |
18,821
-891
| -5% | -$25.8K | ﹤0.01% | 2568 |
|
|
2021
Q3 | $637K | Sell |
19,712
-93
| -0.5% | -$3.09K | ﹤0.01% | 2437 |
|
|
2021
Q2 | $606K | Sell |
19,805
-2,921
| -13% | -$84.4K | ﹤0.01% | 2468 |
|
|
2021
Q1 | $691K | Buy |
22,726
+6,911
| +44% | +$196K | ﹤0.01% | 2263 |
|
|
2020
Q4 | $313K | Buy |
15,815
+1,172
| +8% | +$18.9K | ﹤0.01% | 2575 |
|
|
2020
Q3 | $190K | Sell |
14,643
-12,104
| -45% | -$153K | ﹤0.01% | 2633 |
|
|
2020
Q2 | $303K | Buy |
26,747
+3,424
| +15% | +$48.6K | ﹤0.01% | 2356 |
|
|
2020
Q1 | $332K | Sell |
23,323
-57,357
| -71% | -$1.21M | ﹤0.01% | 2112 |
|
|
2019
Q4 | $2.2M | Buy |
80,680
+55,054
| +215% | +$1.51M | ﹤0.01% | 1275 |
|
|
2019
Q3 | $733K | Sell |
25,626
-50,801
| -66% | -$1.48M | ﹤0.01% | 1946 |
|
|
2019
Q2 | $2.12M | Buy |
76,427
+61,276
| +404% | +$1.73M | 0.01% | 1291 |
|
|
2019
Q1 | $504K | Sell |
15,151
-58,519
| -79% | -$1.78M | ﹤0.01% | 2058 |
|
|
2018
Q4 | $2.14M | Buy |
73,670
+13,285
| +22% | +$478K | 0.01% | 1117 |
|
|
2018
Q3 | $2.78M | Buy |
60,385
+3,317
| +6% | +$147K | 0.01% | 1095 |
|
|
2018
Q2 | $2.13M | Buy |
57,068
+2,925
| +5% | +$98.8K | 0.01% | 1175 |
|
|
2018
Q1 | $1.6M | Buy |
54,143
+635
| +1% | +$21.5K | 0.01% | 1284 |
|
|
2017
Q4 | $1.84M | Sell |
53,508
-900
| -2% | -$30.4K | 0.01% | 1190 |
|
|
2017
Q3 | $1.97M | Buy |
54,408
+1,900
| +4% | +$54.2K | 0.01% | 1134 |
|
|
2017
Q2 | $1.36M | Buy |
+52,508
| New | +$1.11M | 0.01% | 1295 |
|
|
2016
Q1 | – | Sell |
-10,718
| Closed | -$463K | – | 2333 |
|
|
2015
Q4 | $463K | Buy |
+10,718
| New | +$453K | ﹤0.01% | 1706 |
|
|
2014
Q4 | – | Sell |
-7,053
| Closed | -$272K | – | 2401 |
|
|
2014
Q3 | $272K | Buy |
+7,053
| New | +$263K | ﹤0.01% | 1846 |
|
|
2014
Q2 | – | Sell |
-10,184
| Closed | -$348K | – | 2239 |
|
|
2014
Q1 | $348K | Buy |
+10,184
| New | +$316K | ﹤0.01% | 1632 |
|
Other funds holding MYGN
CCM
GCM
Stifel Financial's MYGN Position: Q1 2024 in Review
Stifel Financial sold out of Myriad Genetics (MYGN) in Q1 2024, closing a stake of 19,247 shares — an estimated $368K sold.
Stifel Financial first reported a position in MYGN in Q1 2014 and held it in 30 quarters. The position peaked at $2.78M in Q3 2018. 186 funds tracked by Wall St. Rank hold MYGN as of Q1 2024.
- Stifel Financial reported no remaining Myriad Genetics position as of Q1 2024 after selling out during the quarter.
- Stifel Financial sold 19,247 Myriad Genetics shares in Q1 2024, an estimated $368K.
- Stifel Financial first reported a position in Myriad Genetics in Q1 2014 and held it in 30 quarters.
- Stifel Financial's Myriad Genetics position peaked at $2.78M in Q3 2018.
- 186 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2024.
Based on Stifel Financial's 13F filing for Q1 2024, filed 14 May 2024.